Search results
Aug 7, 2023 · Dr. Silber joins Vigil from Nocion Therapeutics, where he was Chief Medical Officer and led the clinical strategy for the company’s small molecule platform, including development of NTX-1175, a new chemical entity for cough indications.
Aug 8, 2023 · Vigil Neuroscience, Inc. announced the appointment of Christopher J. Silber, M.D. as Chief Medical Officer. Dr. Silber brings over 30 years of biopharmaceutical industry experience and a track record...
Jan 29, 2016 · Agilis Biotherapeutics Names Former Lundbeck Executive, Christopher J. Silber, MD, as Chief Medical Officer. CAMBRIDGE, Mass.-- (BUSINESS WIRE)--Agilis Biotherapeutics, LLC (Agilis), a ...
Dr. Silber earned his B.A. in Psychology from Tufts University and his M.D. at Jacobs School of Medicine and...
WATERTOWN, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced the appointment of Christopher J. Silber, M.D. as Chief Medical Officer.
Aug 7, 2023 · Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of
Jan 25, 2016 · CAMBRIDGE, Mass.--(BUSINESS WIRE)--Agilis Biotherapeutics, LLC (Agilis), a biotechnology company advancing innovative gene therapy products for the treatment of rare genetic diseases that affect the central nervous system (CNS), announced today that the Company has appointed Christopher J Silber, MD, as its Chief Medical Officer.
